News
Xention and Ono Extend Drug Discovery Agreement
12 April 2011
Collaboration to continue for a third year
Xention to Present on the Role of Ion Channels in Pain
22 March 2011
Dr David Madge to review current understanding of ion channels in pain at Berlin ion channel meeting
Xention Participates in €12 Million Atrial Fibrillation Research Consortium
15 March 2011
Consortium awarded five-year European Union grant under Seventh Framework programme
Xention and Grünenthal Enter Drug Discovery Collaboration in Ion Channel Research
15 February 2011
Research collaboration to focus on development of novel pain therapeutic
Xention Spins Out Overactive Bladder Business
16 December 2010
Demerged OAB company to be called Provesica
Xention Raises £8 Million in Private Equity Placement
23 November 2010
Funding to progress development of novel heart arrhythmia drugs
Xention Participates in €6 Million Marine Resources for Bioactive Compounds Research Consortium
15 September 2010
Consortium awarded four-year European Union grant under Seventh Framework programme
Xention Participates in Autoimmune Disorder Research Partnership
1 June 2010
Partnership between Xention Ltd. and Axxam SpA is awarded two-year European Union grant under the Eurostars Programme
Xention Strengthens Team with Director of Finance
6 April 2010
Xention Strengthens Team with Director of Finance
Xention Announces Attendance at Three Upcoming Conferences
14 September 2009
Xention is pleased to announce that it will be presenting at three investor and partnering conferences over the coming weeks.
Xention Limited Receives Wellcome Trust Award For Atrial Fibrillation Programme
6 July 2009
Xention has announced that it has received a substantial award from the Wellcome Trust (“Wellcome”) to support pioneering work on an exciting target for atrial fibrillation.
Xention Limited Builds Team with Appointment of Chief Medical Officer
8 June 2009
Xention has announced the appointment of Dr Patrick Round as Chief Medical Officer and Head of Development.
Xention Enters Drug Discovery Agreement with Ono Pharmaceutical Co., Ltd.
12 March 2009
Xention has announced that it has signed a Drug Discovery Agreement with Ono Pharmaceutical Co., Ltd. of Osaka, Japan (“Ono”).
Xention Limited Appoints Dr Keith McCullagh as New Chairman of its Board
2 February 2009
Xention has announced the appointment of Dr Keith McCullagh as the new non-executive Chairman of its Board of Directors.